Perucca E. Antiepileptic drugs: evolution of our knowledge and changes in drug trials. Epileptic Disord. 2019;21(4):319–29. https://doi.org/10.1684/epd.2019.1083.
Article
PubMed
Google Scholar
Moshé SL, Perucca E, Ryvlin P, Tomson T. Epilepsy: new advances. Lancet. 2015;385(9971):884–98. https://doi.org/10.1016/S0140-6736(14)60456-6.
Article
PubMed
Google Scholar
Perucca E, Brodie MJ, Kwan P, Tomson T. 30 years of second-generation antiseizure medications: impact and future perspectives. Lancet Neurol. 2020;19(6):544–56. https://doi.org/10.1016/S1474-4422(20)30035-1.
Article
CAS
PubMed
Google Scholar
Dalic L, Cook MJ. Managing drug-resistant epilepsy: challenges and solutions. Neuropsychiatr Dis Treat. 2016;12:2605–16. https://doi.org/10.2147/NDT.S84852.
Article
CAS
PubMed
PubMed Central
Google Scholar
Perucca P, Scheffer IE, Kiley M. The management of epilepsy in children and adults. Med J Aust. 2018;208(5):226–33. https://doi.org/10.5694/mja17.00951.
Article
PubMed
Google Scholar
Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. Lancet Neurol. 2011;10(5):446–56. https://doi.org/10.1016/S1474-4422(11)70047-3.
Article
CAS
PubMed
Google Scholar
Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49(7):1239–76. https://doi.org/10.1111/j.1528-1167.2008.01561.x.
Article
CAS
PubMed
Google Scholar
Zaccara G, Perucca E. Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. Epileptic Disord. 2014;16(4):409–31. https://doi.org/10.1684/epd.2014.0714.
Article
PubMed
Google Scholar
Schmidt D. Drug treatment strategies for epilepsy revisited: starting early or late? One drug or several drugs? Epileptic Disord. 2016;18(4):356–66. https://doi.org/10.1684/epd.2016.0882.
Article
PubMed
Google Scholar
Lamberink HJ, Otte WM, Geerts AT, Pavlovic M, Ramos-Lizana J, Marson AG, et al. Individualised prediction model of seizure recurrence and long-term outcomes after withdrawal of antiepileptic drugs in seizure-free patients: a systematic review and individual participant data meta-analysis. Lancet Neurol. 2017;16(7):523–31. https://doi.org/10.1016/S1474-4422(17)30114-X.
Article
PubMed
Google Scholar
Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):1000–15. https://doi.org/10.1016/S0140-6736(07)60460-7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. 2007b;369(9566):1016–26. https://doi.org/10.1016/S0140-6736(07)60461-9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Marson A, Burnside G, Appleton R, Smith D, Leach JP, Sills G, et al. The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet. 2021;397(10282):1363–74. https://doi.org/10.1016/S0140-6736(21)00247-6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Marson A, Burnside G, Appleton R, Smith D, Leach JP, Sills G, et al. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet. 2021;397(10282):1375–86. https://doi.org/10.1016/S0140-6736(21)00246-4.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gesche J, Khanevski M, Solberg C, Beier CP. Resistance to valproic acid as predictor of treatment resistance in genetic generalized epilepsies. Epilepsia. 2017;58(4):e64–9. https://doi.org/10.1111/epi.13702.
Article
CAS
PubMed
Google Scholar
Meador K. Teratogenicity and antiseizure medications. Epilepsy Curr. 2020;20(6_suppl):15S–7S.
Article
Google Scholar
Tomson T, Battino D, Perucca E. Teratogenicity of antiepileptic drugs. Curr Opin Neurol. 2019;32(2):246–52. https://doi.org/10.1097/WCO.0000000000000659.
Article
CAS
PubMed
Google Scholar
Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Perucca E, et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018;17(6):530–8. https://doi.org/10.1016/S1474-4422(18)30107-8.
Article
CAS
PubMed
Google Scholar
Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Perucca E, et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology. 2019;93(9):e831–40. https://doi.org/10.1212/WNL.0000000000008001.
Article
PubMed
Google Scholar
Steinhoff BJ, Staack AM. Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience. Ther Adv Neurol Disord. 2019;12:1756286419873518.
Article
Google Scholar
Subramonian A, Farrah K. Brivaracetam versus levetiracetam for epilepsy: a review of comparative clinical safety: Canadian Agency for Drugs and Technologies in Health, Ottawa, Ontario, Canada; 2020. Available at: https://cadth.ca/sites/default/files/pdf/htis/2020/RC1322%20Comparing%202%20Antiepileptic%20Drugs%20Final.pdf (accessed June 8, 2021)
Löscher W, Sills GJ, White HS. The ups and downs of alkyl-carbamates in epilepsy therapy: how does cenobamate differ? Epilepsia. 2021;62(3):596–614. https://doi.org/10.1111/epi.16832.
Article
CAS
PubMed
Google Scholar
Roberti R, De Caro C, Iannone LF, Zaccara G, Lattanzi S, Russo E. Pharmacology of cenobamate: Mechanism of action, pharmacokinetics, drug-drug interactions and tolerability. CNS Drugs. 2021. https://doi.org/10.1007/s40263-021-00819-8 (online ahead of print).
Krauss GL, Klein P, Brandt C, Lee SK, Milanov I, Milovanovic M, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19(1):38–48. https://doi.org/10.1016/S1474-4422(19)30399-0.
Article
CAS
PubMed
Google Scholar
Vossler DG. Remarkably high efficacy of cenobamate in adults with focal-onset seizures: a double-blind, randomized, placebo-controlled trial. Epilepsy Curr. 2020;20(2):85–7. https://doi.org/10.1177/1535759720903032.
Article
PubMed
PubMed Central
Google Scholar
Franco V, Bialer M, Perucca E. Cannabidiol in the treatment of epilepsy: current evidence and perspectives for further research. Neuropharmacology. 2021;185:108442. https://doi.org/10.1016/j.neuropharm.2020.108442.
Article
CAS
PubMed
Google Scholar
Bialer M, Perucca E. Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials. Epilepsia. 2020;61(6):1082–9. https://doi.org/10.1111/epi.16542.
Article
CAS
PubMed
Google Scholar
Ceulemans B, Schoonjans AS, Marchau F, Paelinck BP, Lagae L. Five-year extended follow-up status of 10 patients with Dravet syndrome treated with fenfluramine. Epilepsia. 2016;57(7):e129–34. https://doi.org/10.1111/epi.13407.
Article
CAS
PubMed
Google Scholar
Odi R, Invernizzi RW, Gallily T, Bialer M, Perucca E. Fenfluramine repurposing from weight loss to epilepsy: what we do and do not know. Pharmacol Ther. 2021;226:107866. https://doi.org/10.1016/j.pharmthera.2021.107866.
Article
CAS
PubMed
Google Scholar
Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Perucca P, et al. Progress report on new antiepileptic drugs: a summary of the fifteenth Eilat conference on new antiepileptic drugs and devices (EILAT XV). II. Drugs in more advanced clinical development. Epilepsia. 2020;61(11):2365–85. https://doi.org/10.1111/epi.16726.
Article
CAS
PubMed
Google Scholar
Overwater IE, Rietman AB, van Eeghen AM, de Wit MCY. Everolimus for the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): current perspectives. Ther Clin Risk Manag. 2019;15:951–5. https://doi.org/10.2147/TCRM.S145630.
Article
CAS
PubMed
PubMed Central
Google Scholar
French JA, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388(10056):2153–63. https://doi.org/10.1016/S0140-6736(16)31419-2.
Article
CAS
PubMed
Google Scholar
Fedak Romanowski EM, McNamara NA, Neil EE, Gottlieb-Smith R, Dang LT. Seizure rescue medications for out-of-hospital use in children. J Pediatr. 2021;229:19–25. https://doi.org/10.1016/j.jpeds.2020.10.041.
Article
CAS
PubMed
Google Scholar
Bouw MR, Chung SS, Gidal B, King A, Tomasovic J, Wheless JW, et al. Clinical pharmacokinetic and pharmacodynamic profile of midazolam nasal spray. Epilepsy Res. 2021;171:106567. https://doi.org/10.1016/j.eplepsyres.2021.106567.
Article
CAS
PubMed
Google Scholar
Boddu SHS, Kumari S. A short review on the intranasal delivery of diazepam for treating acute repetitive seizures. Pharmaceutics. 2020;12(12):1167. https://doi.org/10.3390/pharmaceutics12121167.
Article
CAS
Google Scholar
Gidal B, Klein P, Hirsch LJ. Seizure clusters, rescue treatments, seizure action plans: unmet needs and emerging formulations. Epilepsy Behav. 2020;112:107391. https://doi.org/10.1016/j.yebeh.2020.107391.
Article
PubMed
Google Scholar
Fesler JR, Stanton S, Merner K, Ross L, McGinley MP, Bena J, et al. Bridging the gap in epilepsy care: a single-center experience of 3700 outpatient tele-epilepsy visits. Epilepsia. 2020;61(8):e95–e100. https://doi.org/10.1111/epi.16619.
Article
PubMed
Google Scholar
Alzamanan MZ, Lim KS, Akmar Ismail M, Abdul GN. Self-management apps for people with epilepsy: systematic analysis. JMIR Mhealth Uhealth. 2021;9(5):e22489. https://doi.org/10.2196/22489.
Article
PubMed
PubMed Central
Google Scholar
Patterson V. The development of a smartphone application to help manage epilepsy in resource-limited settings. Seizure. 2020;79:69–74. https://doi.org/10.1016/j.seizure.2020.03.020.
Article
PubMed
Google Scholar
Giuliano L, Cicero CE, Trimarchi G, Todaro V, Colli C, Crespo Gómez EB, et al. Usefulness of a smartphone application for the diagnosis of epilepsy: validation study in high-income and rural low-income countries. Epilepsy Behav. 2021;115:107680. https://doi.org/10.1016/j.yebeh.2020.107680.
Article
PubMed
Google Scholar
Asadi-Pooya AA, Beniczky S, Rubboli G, Sperling MR, Rampp S, Perucca E. A pragmatic algorithm to select appropriate antiseizure medications in patients with epilepsy. Epilepsia. 2020;61(8):1668–77. https://doi.org/10.1111/epi.16610.
Article
PubMed
Google Scholar
Beniczky S, Rampp S, Asadi-Pooya AA, Rubboli G, Perucca E, Sperling MR. Optimal choice of antiseizure medication: agreement among experts and validation of a web-based decision support application. Epilepsia. 2021;62(1):220–7. https://doi.org/10.1111/epi.16763.
Article
PubMed
Google Scholar
Hadady L, Klivényi P, Asadi-Pooya AA, Rampp S, Fabó D, Bereczki C, et al. Web-based decision support system for patient-tailored selection of antiseizure treatment medication in adolescents and adults: An external validation study. 2021 (submitted).
Google Scholar
de Jong J, Cutcutache I, Page M, Elmoufti S, Dilley C, Fröhlich H, et al. Towards realizing the vision of precision medicine: AI based prediction of clinical drug response. Brain. 2021:awab108. https://doi.org/10.1093/brain/awab108 Online ahead of print.
Beniczky S, Wiebe S, Jeppesen J, Tatum WO, Brazdil M, Wang Y, et al. Automated seizure detection using wearable devices: a clinical practice guideline of the international league against epilepsy and the International Federation of Clinical Neurophysiology. Epilepsia. 2021;62(3):632–46. https://doi.org/10.1111/epi.16818.
Article
PubMed
Google Scholar
Rasheed K, Qayyum A, Qadir J, Sivathamboo S, Kwan P, Kuhlmann L, et al. Machine learning for predicting epileptic seizures using EEG signals: a review. IEEE Rev Biomed Eng. 2021;14:139–55. https://doi.org/10.1109/RBME.2020.3008792.
Article
PubMed
Google Scholar
Perucca P, Bahlo M, Berkovic SF. The genetics of epilepsy. Annu Rev Genomics Hum Genet. 2020;21(1):205–30. https://doi.org/10.1146/annurev-genom-120219-074937.
Article
CAS
PubMed
Google Scholar
Daci A, Bozalija A, Jashari F, Krasniqi S. Individualizing treatment approaches for epileptic patients with glucose transporter Type1 (GLUT-1) deficiency. Int J Mol Sci. 2018;19(1):122. https://doi.org/10.3390/ijms19010122.
Article
CAS
PubMed Central
Google Scholar
Perucca P, Perucca E. Identifying mutations in epilepsy genes: impact on treatment selection. Epilepsy Res. 2019;152:18–30. https://doi.org/10.1016/j.eplepsyres.2019.03.001.
Article
CAS
PubMed
Google Scholar
Specchio N, Pietrafusa N, Perucca E, Cross JH. New paradigms for the treatment of pediatric monogenic epilepsies: progressing toward precision medicine. Epilepsy Behav. 2021:107961. https://doi.org/10.1016/j.yebeh.2021.107961 Online ahead of print.
Byrne S, Enright N, Delanty N. Precision therapy in the genetic epilepsies of childhood. Dev Med Child Neurol. 2021. https://doi.org/10.1111/dmcn.14929 Online ahead of print.
Atkin TA, Maher CM, Gerlach AC, Gay BC, Antonio BM, Santos SC, et al. A comprehensive approach to identifying repurposed drugs to treat SCN8A epilepsy. Epilepsia. 2018;59(4):802–13. https://doi.org/10.1111/epi.14037.
Article
CAS
PubMed
Google Scholar
Löscher W, Potschka H, Sisodiya SM, Vezzani A. Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options. Pharmacol Rev. 2020;72(3):606–38. https://doi.org/10.1124/pr.120.019539.
Article
CAS
PubMed
PubMed Central
Google Scholar
Peng J, Pang N, Wang Y, Wang X-L, Chen J, Xiong J. Next-generation sequencing improves treatment efficacy and reduces hospitalization in children with drug-resistant epilepsy. CNS Neurosci Ther. 2019;25(1):14–20. https://doi.org/10.1111/cns.12869.
Article
CAS
PubMed
Google Scholar
Balestrini S, Chiarello D, Gogou M, Silvennoinen K, Puvirajasinghe C, Jones WD, et al. Real-life survey of pitfalls and successes of precision medicine in genetic epilepsies. J Neurol Neurosurg Psychiatry. 2021:jnnp-2020-325932. https://doi.org/10.1136/jnnp-2020-325932 Online ahead of print.
Kobylarek D, Iwanowski P, Lewandowska Z, Limphaibool N, Szafranek S, Labrzycka A, et al. Advances in the potential biomarkers of epilepsy. Front Neurol. 2019;10:685. https://doi.org/10.3389/fneur.2019.00685.
Article
PubMed
PubMed Central
Google Scholar
Engel J Jr, Pitkänen A. Biomarkers for epileptogenesis and its treatment. Neuropharmacology. 2020;167:107735. https://doi.org/10.1016/j.neuropharm.2019.107735.
Article
CAS
PubMed
Google Scholar
Chang CJ, Chen CB, Hung SI, Ji C, Chung WH. Pharmacogenetic testing for prevention of severe cutaneous adverse drug reactions. Front Pharmacol. 2020;11:969. https://doi.org/10.3389/fphar.2020.00969.
Article
CAS
PubMed
PubMed Central
Google Scholar
Simonato M, Agoston DV, Brooks-Kayal A, Dulla C, Fureman B, Henshall DC, et al. Identification of clinically relevant biomarkers of epileptogenesis - a strategic roadmap. Nat Rev Neurol. 2021;17(4):231–42. https://doi.org/10.1038/s41582-021-00461-4.
Article
PubMed
Google Scholar
Galanopoulou AS, Löscher W, Lubbers L, O'Brien TJ, Staley K, Vezzani A, et al. Antiepileptogenesis and disease modification: Progress, challenges, and the path forward-report of the preclinical working group of the 2018 NINDS-sponsored antiepileptogenesis and disease modification workshop. Epilepsia Open. 2021;6(2):276–96. https://doi.org/10.1002/epi4.12490.
Article
PubMed
PubMed Central
Google Scholar
Kearney H, Byrne S, Cavalleri GL, Delanty N. Tackling epilepsy with high-definition precision medicine: a review. JAMA Neurol. 2019;76(9):1109–16. https://doi.org/10.1001/jamaneurol.2019.2384.
Article
PubMed
Google Scholar
Klein P, Friedman A, Hameed MQ, Kaminski RM, Bar-Klein G, Klitgaard H, et al. Repurposed molecules for antiepileptogenesis: missing an opportunity to prevent epilepsy? Epilepsia. 2020;61(3):359–86. https://doi.org/10.1111/epi.16450.
Article
CAS
PubMed
PubMed Central
Google Scholar
Han Z, Chen C, Christiansen A, Ji S, Lin Q, Anumonwo C, et al. Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome. Sci Transl Med. 2020;12(558):eaaz6100.
Article
Google Scholar
Ahonen S, Nitschke S, Grossman TR, Kordasiewicz H, Wang P, Zhao X, et al. Gys1 antisense therapy rescues neuropathological bases of murine Lafora disease. Brain. 2021:awab194. https://doi.org/10.1093/brain/awab194 Online ahead of print.
Higurashi N, Broccoli V, Hirose S. Genetics and gene therapy in Dravet syndrome. Epilepsy Behav. 2021:108043. https://doi.org/10.1016/j.yebeh.2021.108043 Online ahead of print.
Cook M, Murphy M, Bulluss K, D'Souza W, Plummer C, Priest E, et al. Anti-seizure therapy with a long-term, implanted intra-cerebroventricular delivery system for drug-resistant epilepsy: a first-in-man study. EClinicalMedicine. 2020;22:100326. https://doi.org/10.1016/j.eclinm.2020.100326.
Article
PubMed
PubMed Central
Google Scholar
Löscher W. The holy grail of epilepsy prevention: preclinical approaches to antiepileptogenic treatments. Neuropharmacology. 2020;167:107605. https://doi.org/10.1016/j.neuropharm.2019.04.011.
Article
CAS
PubMed
Google Scholar
Rahman MH, Akter R, Kamal MA. Prospective function of different antioxidant containing natural products in the treatment of neurodegenerative disease. CNS Neurol Disord drug targets 2020 Jul 22. Doi: https://doi.org/10.2174/1871527319666200722153611. Online ahead of print.
Leavy A, Jimenez Mateos EM. Perinatal brain injury and inflammation: lessons from experimental murine models. Cells. 2020;9(12):2640. https://doi.org/10.3390/cells9122640.
Article
CAS
PubMed Central
Google Scholar
Yang N, Guan QW, Chen FH, Xia QX, Yin XX, Zhou HH, et al. Antioxidants targeting mitochondrial oxidative stress: promising neuroprotectants for epilepsy. Oxidative Med Cell Longev. 2020:6687185. https://doi.org/10.1155/2020/6687185.
Zavala-Tecuapetla C, Cuellar-Herrera M, Luna-Munguia H. Insights into potential targets for therapeutic intervention in epilepsy. Int J Mol Sci. 2020;21(22):8573. https://doi.org/10.3390/ijms21228573.
Article
CAS
PubMed Central
Google Scholar
Frajewicki A, Laštůvka Z, Borbélyová V, Khan S, Jandová K, Janišová K, et al. Perinatal hypoxic-ischemic damage: review of the current treatment possibilities. Physiol Res. 2020;69(Suppl 3):S379–401. https://doi.org/10.33549/physiolres.934595.
Article
CAS
PubMed
Google Scholar
Murugan M, Boison D. Ketogenic diet, neuroprotection, and antiepileptogenesis. Epilepsy Res. 2020;167:106444. https://doi.org/10.1016/j.eplepsyres.2020.106444.
Article
CAS
PubMed
Google Scholar
Stone NL, Murphy AJ, England TJ, O'Sullivan SE. A systematic review of minor phytocannabinoids with promising neuroprotective potential. Br J Pharmacol. 2020;177(19):4330–52. https://doi.org/10.1111/bph.15185.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sanz P, Serratosa JM, Sánchez MP. Beneficial effects of metformin on the central nervous system, with a focus on epilepsy and Lafora disease. Int J Mol Sci. 2021;22(10):5351. https://doi.org/10.3390/ijms22105351.
Article
CAS
PubMed
PubMed Central
Google Scholar
Tesfaye BA, Hailu HG, Zewdie KA, Ayza MA, Berhe DF. Montelukast: the new therapeutic option for the treatment of epilepsy. J Exp Pharmacol. 2021;13:23–31. https://doi.org/10.2147/JEP.S277720.
Article
PubMed
PubMed Central
Google Scholar
Kotulska K, Kwiatkowski DJ, Curatolo P, Weschke B, Riney K, Jansen F, et al. Prevention of epilepsy in infants with tuberous sclerosis complex in the EPISTOP trial. Ann Neurol. 2021;89(2):304–14. https://doi.org/10.1002/ana.25956.
Article
CAS
PubMed
Google Scholar
Franco V, French JA, Perucca E. Challenges in the clinical development of new antiepileptic drugs. Pharmacol Res. 2016;103:95–104. https://doi.org/10.1016/j.phrs.2015.11.007.
Article
PubMed
Google Scholar